Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

Thumbnail for The best Venetoclax dosing schedule in high-risk Myelodysplastic Syndrome (MDS)

MDS - 644

The best Venetoclax dosing schedule in high-risk Myelodysplastic Syndrome (MDS)

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Real-World Outcomes of Imetelstat: Interrogating Safety, Efficacy, and Predictors of Response in Heavily Pretreated Lower-Risk Patients With MDS

MDS - 646

Real-World Outcomes of Imetelstat: Interrogating Safety, Efficacy, and Predictors of Response in Heavily Pretreated Lower-Risk Patients With MDS

Rami Komrokji

Poster Presenter: Rami Komrokji

Thumbnail for Social Isolation and Loneliness in Hematologic Malignancies: A National Inpatient Sample Analysis 2017-2022

MDS - 695

Social Isolation and Loneliness in Hematologic Malignancies: A National Inpatient Sample Analysis 2017-2022

Preetham Ezhilarasu

Poster Presenter: Preetham Ezhilarasu

Thumbnail for Excess Mortality in Myelodysplastic Neoplasms With Ring Sideroblasts Compared With the Spanish General Population a GESMD Registry Study

MDS - 700

Excess Mortality in Myelodysplastic Neoplasms With Ring Sideroblasts Compared With the Spanish General Population a GESMD Registry Study

Pina Gabriela G?lvez Zavala

Poster Presenter: Pina Gabriela G?lvez Zavala

Thumbnail for Synergistic Epigenetic-Cohesin Disruption in Myelodysplastic Syndromes: ASXL1/STAG2 Defines an UltraΏ½High-Risk Phenotype Amenable to BCL-2 Inhibition

MDS - 717

Synergistic Epigenetic-Cohesin Disruption in Myelodysplastic Syndromes: ASXL1/STAG2 Defines an UltraΏ½High-Risk Phenotype Amenable to BCL-2 Inhibition

Yazan Abushukair

Poster Presenter: Yazan Abushukair

Thumbnail for Danicopan Add-On Therapy to Ravulizumab or Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis Stratified by Bone Marrow Failure History

MDS - 748

Danicopan Add-On Therapy to Ravulizumab or Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis Stratified by Bone Marrow Failure History

Ying Tang

Poster Presenter: Ying Tang

Thumbnail for Comparative Efficacy and Safety of Oral Azacitidine (CC-486) Versus Injectable Hypomethylating Agents as Maintenance Therapy Following Allogeneic Haematopoietic Cell Transplantation in Myelodysplastic Neoplasms: A Systematic Review and Network Meta-Analysis

MDS - 749

Comparative Efficacy and Safety of Oral Azacitidine (CC-486) Versus Injectable Hypomethylating Agents as Maintenance Therapy Following Allogeneic Haematopoietic Cell Transplantation in Myelodysplastic Neoplasms: A Systematic Review and Network Meta-Analysis

Abhinav M

Poster Presenter: Abhinav M

Thumbnail for Real-World Outcomes With Early Adoption of Imetelstat in Patients With Transfusion-Dependent Myelodysplastic Syndromes (MDS): Insights From a United States (US) Community Oncology Chart Review

MDS - 775

Real-World Outcomes With Early Adoption of Imetelstat in Patients With Transfusion-Dependent Myelodysplastic Syndromes (MDS): Insights From a United States (US) Community Oncology Chart Review

Jessy Thomas

Poster Presenter: Jessy Thomas

Thumbnail for Leukemic Transformation and Clinical Outcomes in Thrombocytopenic Myelodysplastic Syndrome Patients Treated with Thrombopoietin Receptor Agonists: A Real-World TriNetX Cohort Study

MDS - 782

Leukemic Transformation and Clinical Outcomes in Thrombocytopenic Myelodysplastic Syndrome Patients Treated with Thrombopoietin Receptor Agonists: A Real-World TriNetX Cohort Study

Madhu Bhargavi Chandra

Poster Presenter: Madhu Bhargavi Chandra

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.